Asset
.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02956122 | phase2_3 | terminated | 2017-04-26 | 2018-05-03 | Baxalta now part of Shire | A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD |
| NCT02525861 | phase3 | completed | 2016-03-08 | 2020-07-29 | Baxalta now part of Shire | GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study |
| NCT02722304 | phase3 | terminated | 2016-11-02 | 2018-09-14 | Baxalta now part of Shire | Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| BLA 125039 | BLA | Takeda Pharmaceuticals U.S.A., Inc. |
| BLA 125325 | BLA | Takeda Pharmaceuticals U.S.A., Inc. |
Marketed products (5)
- Aralast, Aralast Np
- Aralast, Aralast Np
- Glassia
- Glassia
- Glassia